 New York, NY, and Tel Aviv, ISRAEL, Jan. 12, 2022 GLOBE NEWSWIRE -- via NewMediaWire -- Todos Medical, Ltd. OTCQB: TOMDF,a comprehensive medical diagnostics and related solutions company, together with its 3CL biology-focused joint venture partner NLC Pharma, today announced that topline results from the TollovirTM Phase 2 clinical trial for the treatment of hospitalized COVID-19 patients will be announced the morning of January 27th, 2022, with a conference call follow-up that will occur after market close. The Company will provide further details regarding the conference call during the week ending January 17, 2022 when it announces the data lock for the trial. 